Tech Company Inital Public Offerings
Aduro BioTech IPO
Aduro BioTech was acquired by . Shares were listed on 4/15/2015.
Transaction Overview
Company Name
Announced On
4/15/2015
Transaction Type
IPO
Amount
$119,000,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
740 Heinz Ave.
Berkeley, CA 94710
USA
Berkeley, CA 94710
USA
Phone
Website
Email Address
Overview
Aduro Biotech is a clinical-stage cancer immunotherapy company, the company's lead candidate -- an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Isaacs
Chief Medical Officer
Natalie Sacks
Chief Operating Officer
Gregory Schafer
Chief Operating Officer
Hans van Eenennaam
Chief Scientific Officer
Andrea van Elsas
Vice President
Anne Moon
VP - Bus. Development
Aimee Murphy
VP - Finance
Jennifer Lew
VP - General Counsel
Celeste Ferber
VP - General Counsel
Blaine Templeman
VP - Human Resources
Nancy Kaplan
VP - Operations
Quoc Le-Nguyen
VP - Operations
Aimee Murphy
VP - Operations
Justin Skoble
VP - R & D
Dirk Brockstedt
VP - Regulatory Affairs
Michele DeVries
VP - Regulatory Affairs
Sylvia Wheeler
Browse more venture capital transactions:
Prev: 4/15/2015: RetailNext venture capital transaction
Next: 4/15/2015: Oligomerix venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs